Inhibitory effect of therapeutic medicine on liver disease progression in metabolic dysfunction-associated fatty liver disease patient

Inhibitory effect of therapeutic medicine on liver disease progression in metabolic dysfunction-associated fatty liver disease patient - Inhibitory effect of therapeutic medicine on liver disease progression in metabolic dysfunction-associated fatty liver disease patient

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044364

Enrollment

500

Registered

2021-06-21

Start date

2021-05-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic dysfunction-associated fatty liver disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients aged 20 years or older at the time of obtaining consent 2.Those who have received sufficient explanation before participating in this study, and who have obtained the voluntary consent of the research subject after sufficient understanding.

Exclusion criteria

Exclusion criteria: 1.Patients with heart disease (myocardial infarction, heart failure, arrhythmia, etc.) that is difficult to control 2.In addition, patients who the principal investigator deems inappropriate as research subjects

Design outcomes

Primary

Measure	Time frame
Searching for the association between therapeutic medicine and liver disease progression in metabolic dysfunction-associated fatty liver disease	—

Countries

Japan

Contacts

Public ContactGoki Suda

Hokkaido University Hospital Gastroenterology

gsudgast@pop.med.hokudai.ac.jp011-716-1161

Outcome results